Discovery and development of selective PPARγ modulators as safe and effective antidiabetic agents

This publication has 131 references indexed in Scilit:

• Nuclear Receptor-Coregulator Interaction Profiling Identifies TRIP3 as a Novel Peroxisome Proliferator-activated Receptor γ Cofactor
  Molecular & Cellular Proteomics, 2009
• Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent
  Proceedings of the National Academy of Sciences, 2009
• MBX‐102/JNJ39659100, a Novel Non‐TZD Selective Partial PPAR‐γ Agonist Lowers Triglyceride Independently of PPAR‐α Activation
  PPAR Research, 2009
• The genetic ablation of SRC-3 protects against obesity and improves insulin sensitivity by reducing the acetylation of PGC-1α
  Proceedings of the National Academy of Sciences, 2008
• The Development of INT131 as a Selective PPARγ Modulator: Approach to a Safer Insulin Sensitizer
  PPAR Research, 2008
• PPARγ signaling exacerbates mammary gland tumor development
  Genes & Development, 2004
• Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription
  Cell, 2000
• Activation of Human Peroxisome Proliferator-Activated Receptor (PPAR) Subtypes by Pioglitazone
  Biochemical and Biophysical Research Communications, 2000
• Terminal Differentiation of Human Breast Cancer through PPARγ
  Molecular Cell, 1998
• mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.
  Genes & Development, 1994